Connective tissue diseases by the numbers

Size: px
Start display at page:

Download "Connective tissue diseases by the numbers"

Transcription

1 AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Connective tissue diseases by the numbers Connective tissue diseases are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. The report examined prevalence, economic burdens, and mortality for skin disease in the U.S. using 2013 health care claims data drawn from insurance enrollment and claims databases and found that: 84.5 million Americans one in four saw a physician for skin disease; 50% of them are over 65 and have an average of 2.2 skin conditions. Skin disease cost the U.S. healthcare system $75 billion in medical, preventative, and prescription and non-prescription drug costs. One in three Americans with skin disease were seen by a dermatologist, who collaborate with other physicians throughout the health care system in caring for these patients. Connective tissue diseases include serious conditions such as lupus, dermatomyositis, scleroderma, and diffuse connective tissue disease which together resulted in nearly 1,400 deaths in That year, connective tissue diseases: Affected more than 1.16 million individuals, primarily adults. Were among the top 5 costliest skin diseases per patient at $1,177; total medical costs were $1.38 billion. Resulted in lost productivity costs for individuals and caregivers of $122 million, higher than that of psoriasis or melanoma. Decreased the average of lifespan of 75 years by almost 19 years, more than twice as much as all other causes of death. The charts that follow provide topline data on how connective tissue diseases contribute to the overall burden of skin disease. The full report includes data on prescription and non-prescription drug costs, and how age and insurance status and provider relate to the burden associated with connective tissue diseases and skin disease broadly. To purchase the report visit

2 Prevalance NUMBER OF CARED-FOR INDIVIDUALS TISSUE 30,000,000 25,000,000 20,000,000 15,000,000 10,000,000 5,000, ,169,094 NON-CANCEROUS SKIN GROWTHS* VIRAL AND FUNGAL WOUNDS AND BURNS CONTACT DERMATITIS TISSUE *This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc. TISSUE DISEASE PATIENTS BY AGE* 50.0% 45.0% 44.0% 40.0% 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% 23.9% 0.34% 30.3% 5.0% 0.0% 1.9% *Percentage of connective tissue disease patients seen by a physician by age group.

3 Cost TOTAL MEDICAL COST* TISSUE (IN MILLIONS USD) $9,000 $8,000 $7,000 $6,000 $5,000 $4,000 $3,000 $8,135 $7,015 $6,398 $6,052 $5,442 $2,000 $1,000 $0 $1,375 NON-CANCEROUS SKIN GROWTHS** WOUNDS AND BURNS SKIN CANCER*** ULCERS TISSUE * In millions of dollars compared to most costly skin diseases. **This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc. ***Represents combined data for melanoma and nonmelanoma skin cancer. COST OF SKIN DISEASE PER AFFECTED PERSON* TISSUE $3, $3, $2, $2, $1, $1, $1, $ $0.00 LYMPHOMA SKIN CANCER** ULCERS TISSUE BULLOUS *Compared with most costly skin diseases. **Represents combined data for melanoma and nonmelanoma skin cancer.

4 Life Impact MORTALITY* TISSUE 5,000 4,500 4,000 NUMBER OF DEATHS IN ,500 3,000 2,500 2,000 1,500 1, , Y SKIN CANCER 3, Y WOUNDS AND BURNS 2, Y 1, Y ULCERS 1, Y TISSUE *Provides the total number of deaths and average age at death from connective tissue diseases compared with other skin diseases with highest mortality. YEARS OF POTENTIAL LIFE LOST* TISSUE TOTAL SKIN ALL CAUSES OF DEATH ALL CAUSES OF DEATH TOTAL SKIN WOUNDS AND BURNS CONGENITAL ABNORMALITIES TISSUE *Estimate/projected number of life years lost due to connective tissue diseases compared to top skin diseases leading to early death; Projected based on prototypical lifespan of 75 years.

5 Life Impact LOST PRODUCTIVITY (OPPORTUNITY COST)* TISSUE $2,500 (IN MILLIONS USD) $2,000 $1,500 $1,000 $1,924 $1,570 $1,413 $940 $699 $500 $0 $122 NON-CANCEROUS WOUNDS SKIN GROWTHS** AND BURNS VIRAL AND FUNGAL DISEASE CONTACT DERMATITIS TISSUE *Time lost by patients and/or caregivers multiplied by average wages in 2013 ($192/day); In millions of dollars compared with skin diseases leading to the most loss of productivity. **This category is clinically broad in nature and includes, among other diseases: benign neoplasms, melanocytic nevi (unspecified), pilar cysts, pilonidal cysts (with or without abscess), scars and fibrosis, etc.

6 This information is intended for personal/noncommercial use and may not be reproduced in any form by any means (electronic, mechanical, or other) or held in any information storage and retrieval systems without written permission from the publisher. Commercial use or distribution For information on obtaining copies of this publication or to license the content for distribution, please visit for details and to complete an application. REV 05/05/

Bullous diseases by the numbers

Bullous diseases by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Bullous diseases by the numbers Bullous diseases are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Skin infections by the numbers

Skin infections by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Skin infections by the numbers Skin infections are among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Skin cancer by the numbers

Skin cancer by the numbers AMERICAN ACADEMY OF DERMATOLOGY DISEASE BRIEFS Skin cancer by the numbers Melanoma and nonmelanoma (basal and squamous cell carcinoma) skin cancers are among 24 skin diseases or disease categories examined

More information

Congenital abnormalities. by the numbers

Congenital abnormalities. by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Congenital abnormalities by the numbers Congenital abnormalities are among 24 skin diseases or disease categories examined in the Burden of Skin Disease

More information

Contact dermatitis by the numbers

Contact dermatitis by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Contact dermatitis by the numbers Contact dermatitis is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned

More information

Psoriasis by the numbers

Psoriasis by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Psoriasis by the numbers Psoriasis is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the

More information

Rosacea by the numbers

Rosacea by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Rosacea by the numbers Rosacea is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American

More information

Acne by the numbers. The charts that follow provide topline data on how acne contributes to the overall burden of skin disease.

Acne by the numbers. The charts that follow provide topline data on how acne contributes to the overall burden of skin disease. AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Acne by the numbers Acne is among 24 skin diseases or disease categories examined in the Burden of Skin Disease report commissioned by the American Academy

More information

Hair and nail disorders by the numbers

Hair and nail disorders by the numbers AMERICAN ACADEMY OF DERMATOLOGY SKIN DISEASE BRIEFS Hair and nail disorders by the numbers Hair and nail disorders are among 24 skin diseases or disease categories examined in the Burden of Skin Disease

More information

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S

DESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Policy: Atopic Dermatitis and Topical Antipsoriatics Reference Number: TCHP.PHAR.18004 Effective Date: 01.01.18 Last Review Date: 10.12.18 Line of Business: Oregon Health Plan Revision Log See Important

More information

Asthma Management and the Allergist

Asthma Management and the Allergist Asthma Management and the Allergist Better Outcomes at Lower Cost Executive Summary AllergyandAsthmaRelief.org college.acaai.org/betteroutcomeslowercosts A substantial and growing body of published clinical

More information

A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System

A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System A Review of Medical Malpractice Claims from the CRICO Comparative Benchmarking System (CBS: a national database of medical malpractice claims from captive & commercial insurers across the US ) Note: I

More information

Chapter 6: Healthcare Expenditures for Persons with CKD

Chapter 6: Healthcare Expenditures for Persons with CKD Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial

More information

Re: MassHealth Section 1115 Demonstration Waiver Amendment Request, Section 4 ( Waiver Request )

Re: MassHealth Section 1115 Demonstration Waiver Amendment Request, Section 4 ( Waiver Request ) October 20, 2017 Eric Hargan Acting Secretary Department of Health and Human Services Hubert H. Humphrey Building 200 Independence Avenue, SW Washington, D.C. 20201 Re: MassHealth Section 1115 Demonstration

More information

WR SKIN. DERMATOLOGY

WR SKIN. DERMATOLOGY WR SKIN. DERMATOLOGY 1 Societies 11 History 13 Dictionaries. Encyclopaedias. Bibliographies Use for general works only. Classify with specific aspect 15 Classification. Nomenclature 16 Tables. Statistics

More information

Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K

Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K Screening for malignant melanoma: a cost-effectiveness analysis Freedberg K A, Geller A C, Miller D R, Lew R A, Koh H K Record Status This is a critical abstract of an economic evaluation that meets the

More information

VACAVILLE DERMATOLOGY

VACAVILLE DERMATOLOGY Connecting the Dots on those Spots NANDAN V. KAMATH, M.D. VACAVILLE DERMATOLOGY Sources All of the photos were taken with permission from the Dermnet NZ website - Dermnet New Zealand after communicating

More information

Cancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition

Cancer Disparities in Arkansas: An Uneven Distribution. Prepared by: Martha M. Phillips, PhD, MPH, MBA. For the Arkansas Cancer Coalition Cancer Disparities in Arkansas: An Uneven Distribution Prepared by: Martha M. Phillips, PhD, MPH, MBA For the Arkansas Cancer Coalition Table of Contents Page Burden of Cancer 3 Cancer Disparities 3 Cost

More information

Cost-Motivated Treatment Changes in Commercial Claims:

Cost-Motivated Treatment Changes in Commercial Claims: Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical

More information

The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data

The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data National Center on Birth Defects and Developmental Disabilities The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data Scott

More information

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS

BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS BL-5010P A NOVEL PRE-FILLED APPLICATOR FOR THE NON-SURGICAL REMOVAL OF SKIN LESIONS 25 Skin lesions Miri Seiberg, PhD 26 Skin lesions A part of the skin that has an abnormal growth or appearance compared

More information

Impact of Chronic Conditions on Health-Related Quality of Life

Impact of Chronic Conditions on Health-Related Quality of Life BURDEN OF ILLNESS Overview Impact of Chronic Conditions on Health-Related Quality of Life Chronic joint pain conditions have an important impact on health-related quality of life Note: a larger negative

More information

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS.

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. HEALTH FACTS The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. Alzheimer s Association Nebraska Chapter 5.5 million

More information

Dermatology GP Referral Guidelines

Dermatology GP Referral Guidelines Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:

More information

ETG Analyzer Report. Your Practice # Episodes. Mkt Share Mkt Volume WHIO Dermatology 575 Acne 746 $508 1,698 $

ETG Analyzer Report. Your Practice # Episodes. Mkt Share Mkt Volume WHIO Dermatology 575 Acne 746 $508 1,698 $ ETG Analyzer Report Practice: Practice Group: Badger County Severity: Level 1 Payers: Commercial Episode Types: Complete Claims: Full Claims Outliers: No Outliers DMV6 Created: April 1, 2010 March 31,

More information

The impact of pharmaceutical innovation on New Zealand cancer patients

The impact of pharmaceutical innovation on New Zealand cancer patients The impact of pharmaceutical innovation on New Zealand cancer patients Frank R. Lichtenberg, Ph.D Columbia University and National Bureau of Economic Research New medicines have helped people with cancer

More information

UNDERSTANDING ATOPIC DERMATITIS IN THE US

UNDERSTANDING ATOPIC DERMATITIS IN THE US Key points: Resources for training general practitioners to treat atopic dermatitis (AD) remain sparse and inconsistent. A lack of comprehensive data makes it difficult to assess the prevalence of AD in

More information

ORIGINAL INVESTIGATION. Most Common Dermatologic Problems Identified by Internists,

ORIGINAL INVESTIGATION. Most Common Dermatologic Problems Identified by Internists, ORIGINAL INVESTIGATION Most Common Dermatologic Problems Identified by Internists, 1990-1994 Steven R. Feldman, MD, PhD; Alan B. Fleischer, Jr, MD; R. Carol McConnell, BS Background: Internists in all

More information

Texas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar

Texas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Research proposal. The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H.

Research proposal. The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H. 1 Research proposal The impact of medical knowledge accumulation and diffusion on health: evidence from Medline and other N.I.H. data Frank R. Lichtenberg Columbia University and National Bureau of Economic

More information

Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars

Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars Analysis commissioned by The Collins Center for Public Policy / Community Voices Miami AUGUST 2006 Author: Burton

More information

Undergraduate Dermatology Curriculum July 2016

Undergraduate Dermatology Curriculum July 2016 Undergraduate Dermatology Curriculum July 2016 British Association of Dermatologists Introduction This document is the 2016 revised dermatology undergraduate curriculum (UK) from the British Association

More information

ICD-10-CM Cornea. Type RT LT OU SINGLE CODE UNSPECIFIED. Acute atopic conjunctivitis H10.11 H10.12 H10.13 X H10.10

ICD-10-CM Cornea. Type RT LT OU SINGLE CODE UNSPECIFIED. Acute atopic conjunctivitis H10.11 H10.12 H10.13 X H10.10 ICD-10-CM Cornea Conjunctiva Acute atopic conjunctivitis H10.11 H10.12 H10.13 H10.10 Acute chemical conjunctivitis H10.211 H10.212 H10.213 H10.219 Acute conjunctivitis, unspecified H10.31 H10.32 H10.33

More information

Age-related prevalence of dermatoscopic patterns of acral melanocytic nevi

Age-related prevalence of dermatoscopic patterns of acral melanocytic nevi DERMATOLOGY PRACTICAL & CONCEPTUAL www.derm101.com Age-related prevalence of dermatoscopic patterns of acral melanocytic nevi Reiko Suzaki 1, Sumiko Ishizaki 1, Hitoshi Iyatomi 2, Masaru Tanaka 1 1 Department

More information

Health technology Lower-extremity amputation prevention strategies among individuals with diabetes.

Health technology Lower-extremity amputation prevention strategies among individuals with diabetes. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes Ollendorf D A, Kotsanos J G, Wishner W J, Friedman M, Cooper T, Bittoni M, Oster G Record Status This is a critical

More information

COSTS OF HEALTH SERVICES UTILIZATION OF PEOPLE WITH FETAL ALCOHOL SPECTRUM DISORDER BY SEX AND AGE GROUP IN ALBERTA, CANADA

COSTS OF HEALTH SERVICES UTILIZATION OF PEOPLE WITH FETAL ALCOHOL SPECTRUM DISORDER BY SEX AND AGE GROUP IN ALBERTA, CANADA COSTS OF HEALTH SERVICES UTILIZATION OF PEOPLE WITH FETAL ALCOHOL SPECTRUM DISORDER BY SEX AND AGE GROUP IN ALBERTA, CANADA Nguyen Xuan Thanh 1,2, Egon Jonsson 1,2,3 1 Institute of Health Economics, Edmonton,

More information

Contribution of health care factors to the burden of skin disease in the United States

Contribution of health care factors to the burden of skin disease in the United States FROM THE ACADEMY Contribution of health care factors to the burden of disease in the United States HenryW.Lim,MD, a ScottA.B.Collins,MD, b Jack S. Resneck, Jr, MD, c Jean L. Bolognia, MD, d Julie A. Hodge,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Rayos) Reference Number: CP.CPA.273 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Injury Chronic Disease Infant Mortality Maternal & Child Health Infectious Disease Life Expectancy

Injury Chronic Disease Infant Mortality Maternal & Child Health Infectious Disease Life Expectancy Visit WatchUsThrive.org to learn more Welcome to the Community Health Pathway of WeTHRIVE! SM Here you will find a brief Community Health Assessment for your community. This will provide you with health

More information

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION

VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION A snapshot of data on amoxicillin, budesonide, losartan and salbutamol in eight European Union Member States Report INTRODUCTION

More information

Per Capita Health Care Spending on Diabetes:

Per Capita Health Care Spending on Diabetes: Issue Brief #10 May 2015 Per Capita Health Care Spending on Diabetes: 2009-2013 Diabetes is a costly chronic condition in the United States, medical costs and productivity loss attributable to diabetes

More information

US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research

US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research US Wound Dressing Market Size, Share, Growth, Industry Analysis, Competitive Strategies and Forescast to 2024 Hexa Research The U.S. wound dressing market size was valued at USD 3.18 billion in 2017. Increasing

More information

UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty

UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty 666700 Acne Family Medicine, Internal Medicine, Pediatrics 438300 Acute Bronchitis Allergy,

More information

GASTROINTESTINAL IMAGING STUDY GUIDE

GASTROINTESTINAL IMAGING STUDY GUIDE GASTROINTESTINAL IMAGING STUDY GUIDE Pharynx Diverticula Foreign bodies Trauma o Motility Disorders Esophagus Diverticula Trauma Esophagitis Barrett esophagus Rings, webs, and strictures Varices Benign

More information

Calculate a Fraction of a Whole Number

Calculate a Fraction of a Whole Number Calculate a Fraction of a Whole Number Objective: Calculate a fraction of a whole number Terms and Conditions To the best of the producer's knowledge, the academic content of this resource is accurate

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for

More information

DEPARTMENT OF DERMATOLOGY WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MARYLAND

DEPARTMENT OF DERMATOLOGY WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MARYLAND DEPARTMENT OF DERMATOLOGY WALTER REED NATIONAL MILITARY MEDICAL CENTER BETHESDA MARYLAND 20889-5600 04 October 2016 MEMORANDUM FOR DERMATOLOGY CLINIC PERSONNEL SUBJECT: Standard Operating Procedure for

More information

Drug Overdose Morbidity and Mortality in Kentucky,

Drug Overdose Morbidity and Mortality in Kentucky, Drug Overdose Morbidity and Mortality in Kentucky, 2000-2010 An examination of statewide data, including the rising impact of prescription drug overdose on fatality rates, and the parallel rise in associated

More information

Comorbidities and Workers Compensation

Comorbidities and Workers Compensation Comorbidities and Workers Compensation Claim Durations And Costs Kevin Confetti Director, Workers' Compensation Systems and Operations & Employment Practices Liability University of California, Office

More information

Basics in Dermoscopy

Basics in Dermoscopy Basics in Dermoscopy Manal Bosseila Professor of Dermatology, Cairo University Member of European Academy Dermatology & Venereology EADV Member of International Dermoscopy Society IDS Member of Aesthetic

More information

Table 1: One Year Net Survival Rates for All Cancers Excluding Non-Melanoma Skin Cancer:

Table 1: One Year Net Survival Rates for All Cancers Excluding Non-Melanoma Skin Cancer: Task 1: Draw a bar chart of the following data. All the data must be on one graph. The data shows yearly survival rates for all types of cancers combined (except non-melanoma skin cancer). Hint: Each period

More information

Punch 1/25/2017. Coding for Biopsies. Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA. APMA Coding Committee. Editorial Advisory Board, WOUNDS

Punch 1/25/2017. Coding for Biopsies. Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA. APMA Coding Committee. Editorial Advisory Board, WOUNDS Coding for Biopsies Jeffrey D. Lehrman, DPM, FASPS, FACFAS, MAPWCA APMA Coding Committee Editorial Advisory Board, WOUNDS Board of Directors, American Society of Podiatric Surgeons Board of Directors,

More information

Pandemic Flu Impact in U.S.

Pandemic Flu Impact in U.S. Pandemic Flu Impact in U.S. Pandemic Flu and the Potential for U.S. Economic Recession Second worst recession since World War II -- about 5.25% decline in Gross Domestic Product (GDP); $683 billion loss

More information

Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17

Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Novan Provides Update on SB414 Inflammatory Skin Disease Development Program

Novan Provides Update on SB414 Inflammatory Skin Disease Development Program Novan Provides Update on SB414 Inflammatory Skin Disease Development Program SB414 Nitric Oxide-Releasing Cream Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting

More information

Premium Specialty: Pediatrics

Premium Specialty: Pediatrics Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium

More information

Patricia C. McCormack, M.D., F.A.A.D.

Patricia C. McCormack, M.D., F.A.A.D. Patricia C. McCormack, M.D., F.A.A.D. Diplomate of the American Board of Dermatology Adult & Pediatric Dermatology www.patriciamccormackmd.com PATIENT INFORMATION Today s date: Last name: First name: of

More information

THE COST OF DIABETES IN ALBERTA

THE COST OF DIABETES IN ALBERTA THE COST OF DIABETES IN ALBERTA The Alberta Diabetes Cost Model 1 In 2009, the Canadian Diabetes Association commissioned a report, An Economic Tsunami: the Cost of Diabetes in Canada, to determine the

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Welcome and Texas DSHS Overview

Welcome and Texas DSHS Overview Welcome and Texas DSHS Overview July 24, 2015 Heart Attack and Stroke Systems of Care Summit: A Focus on Quality Improvement through the Texas Heart Attack and Stroke Data Collection Initiative Disclosure

More information

Annual High Claims Survey. Year Ending 31 December 2016

Annual High Claims Survey. Year Ending 31 December 2016 Annual High Claims Survey Year Ending 31 December 2016 Released July 2017 Summary The Private Healthcare Australia Annual High Claims Survey Report analyses the nature and magnitude of high claims met

More information

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods:

GSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/Centers: Research Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

DART Clinic Review: Experiences from a combined dermatology and rheumatology clinic

DART Clinic Review: Experiences from a combined dermatology and rheumatology clinic DART Clinic Review: Experiences from a combined dermatology and rheumatology clinic Michael Samycia 1, Collette McCourt 2, Kam Shojania 4, Sheila Au 1,3 1 Department of Dermatology and Skin Science, University

More information

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health MEMORANDUM FOR THE COMMITTEE OF PUBLIC ACCOUNTS HC 125 SESSION 2013-14 21 MAY 2013 Department of Health Access to clinical trial information and the stockpiling of Tamiflu 4 Summary Access to clinical

More information

Wound Management in Urgent Care

Wound Management in Urgent Care Wound Management in Urgent Care Brittany Busse Wound Management in Urgent Care Brittany Busse, MD Med 7 Urgent Care Folsom, CA, USA ISBN 978-3-319-27426-3 DOI 10.1007/978-3-319-27428-7 ISBN 978-3-319-27428-7

More information

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517

Clinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517 Clinical Policy: Implantable Miniature Telescope for Age Related Macular Reference Number: CP.MP.517 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important

More information

Global Influenza Vaccine Market: Industry Analysis & Outlook

Global Influenza Vaccine Market: Industry Analysis & Outlook Industry Research by Koncept Analytics Global Influenza Vaccine Market: Industry Analysis & Outlook ----------------------------------------- January 2017 1 Executive Summary Influenza, also known as flu,

More information

COLLOIDAL SILVER. Compiled by. Campbell M Gold (2009) CMG Archives --()-- IMPORTANT

COLLOIDAL SILVER. Compiled by. Campbell M Gold (2009) CMG Archives  --()-- IMPORTANT COLLOIDAL SILVER Compiled by Campbell M Gold (2009) CMG Archives http://www.campbellmgold.com IMPORTANT The health information contained herein is not meant as a substitute for advice from your physician,

More information

Insurance Guide For Dental Healthcare Professionals

Insurance Guide For Dental Healthcare Professionals Insurance Guide For Dental Healthcare Professionals Dental Benefits Basics What is dental insurance? Unlike traditional insurance, dental benefits are not meant to cover all oral healthcare needs. The

More information

Attending Physician s Statement

Attending Physician s Statement ( Form A A This form is used for claiming the social insurance benefit. This form should be completed and signed by the attending physician outpatient and One form for each month, one form for hospitalization

More information

PHA Annual High Claims Report 2018

PHA Annual High Claims Report 2018 24 October 2018 Medical device costs, increasing complexity and growing numbers of long hospital stays for mental health problems drive high health insurance claims PHA s Annual High Claims 2018 Report

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: itraconazole (Sporanox) Reference Number: HIM.PA.36 Effective Date: 05/16 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important

More information

Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L

Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L Gastric ulcers at endoscopy: brush, biopsy, or both Sadowski D C, Rabeneck L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

More information

DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES

DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES UNC DIVISION OF PLASTIC AND RECONSTRUCTIVE SURGERY DERMATOLOGY ROTATION: COMPETENCY-BASED GOALS AND OBJECTIVES MEDICAL KNOWLEDGE A. Anatomy/Physiology/Embryology Goal: The resident will have knowledge

More information

Cost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY

Cost of Diabetes. Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY Cost of Diabetes Laura Keller Director State Advocacy AK CO HI ID MT ND OR SD WA WY Christopher Stanley, MD, MBA American Diabetes Association Colorado Advocacy Chair Vice President of Population Health

More information

AUTISM SPEAKS RESOURCE IN PUBLIC HEALTH

AUTISM SPEAKS RESOURCE IN PUBLIC HEALTH AUTISM SPEAKS RESOURCE IN PUBLIC HEALTH Andy Shih, PhD Senior Vice President, Public Health & Inclusion Follow Me @ASAndyShih About Autism Speaks Mission Autism Speaks is dedicated to promoting solutions,

More information

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets

More information

Source of effectiveness data The effectiveness evidence was derived from a review of published studies.

Source of effectiveness data The effectiveness evidence was derived from a review of published studies. Cost and cost effectiveness of venous and pressure ulcer protocols of care Kerstein M D, Gemmen E, van Rijswijk L, Lyder C H, Phillips T, Xakellis G, Golden K, Harrington C Record Status This is a critical

More information

Setting The setting was primary care. The economic study was carried out in the UK and the USA.

Setting The setting was primary care. The economic study was carried out in the UK and the USA. Validation of venous leg ulcer guidelines in the United States and United Kingdom McGuckin M, Waterman R, Brooks J, Cherry G, Porten L, Hurley S, Kerstein M D Record Status This is a critical abstract

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date: Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

2019 March. Tobacco Facts: Consumption, Mortality, and Morbidity. Center for Urban Population Health University of Wisconsin-Milwaukee

2019 March. Tobacco Facts: Consumption, Mortality, and Morbidity. Center for Urban Population Health University of Wisconsin-Milwaukee 2019 March Tobacco Facts: Consumption, Mortality, and Morbidity Center for Urban Population Health University of Wisconsin-Milwaukee ACKNOWLEDGEMENTS This report was prepared by Karen A. Palmersheim, Ph.D.,

More information

Supplemental Nutrition Assistance Program (SNAP): A Lifeline for Hungry Mainers

Supplemental Nutrition Assistance Program (SNAP): A Lifeline for Hungry Mainers EXECUTIVE SUMMARY Supplemental Nutrition Assistance Program (SNAP): A Lifeline for Hungry Mainers by Sandra S. Butler, Ph.D. Professor, School of Social Work, University of Maine While the nation makes

More information

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441

Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Effective Date: November 2008 Last Review Date: January 2017 See Important Reminder at the

More information

Maria Parham Cancer Center Henderson NC Annual Report 2013

Maria Parham Cancer Center Henderson NC Annual Report 2013 Maria Parham Cancer Center Henderson NC Annual Report 2013 2013 has been a vibrant year of change for the Maria Parham Cancer Center, changes aimed at improving the quality of patient care as well as patient

More information

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

The Cost Of Functional Dyspepsia Results From A Large US Employer Database

The Cost Of Functional Dyspepsia Results From A Large US Employer Database European ISPOR Meeting Copenhagen, Denmark October 30, 2006 The Cost Of Functional Dyspepsia Results From A Large US Employer Database Researchers: Stephen George, MS, RPh 1, Nathan Kleinman, PhD 2, Richard

More information

The Economic Burden of Hypercholesterolaemia

The Economic Burden of Hypercholesterolaemia The Economic Burden of Hypercholesterolaemia November 2018 TABLE OF CONTENTS Acronyms 3 Executive Summary 4 Introduction 5 Approach 5 Structure of the report 5 Economic burden of hypercholesterolaemia

More information

Clinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18

Clinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18 Clinical Policy: (Exelon) Reference Number: CP.PMN.101 Effective Date: 03.01.17 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

DENTAL RELATED VISITS TO HOSPITAL EMERGENCY ROOMS- PAY ME NOW OR PAY ME LATER Oral Health Florida Conference July 31, 2014 Orlando

DENTAL RELATED VISITS TO HOSPITAL EMERGENCY ROOMS- PAY ME NOW OR PAY ME LATER Oral Health Florida Conference July 31, 2014 Orlando Frank Catalanotto, DMD Professor and Chair Department of Community Dentistry and Behavioral Science University of Florida College of Dentistry College of Dentistry DENTAL RELATED VISITS TO HOSPITAL EMERGENCY

More information

Clinical Policy: Alosetron (Lotronex) Reference Number: CP.CPA.65 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal

Clinical Policy: Alosetron (Lotronex) Reference Number: CP.CPA.65 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal Clinical Policy: (Lotronex) Reference Number: CP.CPA.65 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Introduction to ICD-9 Code Selection. Laura Sullivan, CPC Coordinator Corporate Compliance Auditing & Education Summer 2010

Introduction to ICD-9 Code Selection. Laura Sullivan, CPC Coordinator Corporate Compliance Auditing & Education Summer 2010 Introduction to ICD-9 Code Selection Laura Sullivan, CPC Coordinator Corporate Compliance Auditing & Education Summer 2010 1 Legal Stuff The information provided here is personal opinion only and should

More information

Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the

More information

Total financial cost to the U.S. Direct medical costs: Direct non-medical costs: Productivity losses: TOTAL: $16.2 billion $11.2 billion $8.

Total financial cost to the U.S. Direct medical costs: Direct non-medical costs: Productivity losses: TOTAL: $16.2 billion $11.2 billion $8. 2 Annual Total Burden to the U.S. Economy of AMD, Cataract, Diabetic Retinopathy, Glaucoma, Refractive Errors, Visual Impairment and Blindness Total financial cost to the U.S. For the year 24, the total

More information

Effective Technology and Its Economic Benefits: The Case of Colonoscopy

Effective Technology and Its Economic Benefits: The Case of Colonoscopy Effective Technology and Its Economic Benefits: The Case of Colonoscopy Ross C. DeVol, Chief Research Officer Milken Institute The 2015 Dialogue for Action: Expanding Access Through Innovation Renaissance

More information

A Cross-Sectional Survey of a Dermatology Outpatient Service in Malta

A Cross-Sectional Survey of a Dermatology Outpatient Service in Malta Original Article A Cross-Sectional Survey of a Dermatology Outpatient Service in Malta Susan Aquilina, Andrew Amato Gauci, Michael J Boffa Abstract A survey of the outpatient service provided by a consultant

More information

Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States,

Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States, Morbidity and Mortality Weekly Report (MMWR) Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States, 2004--2008 Weekly June 18, 2010 / 59(23);705-709 Rates

More information

Financial Impact of Emergency Department Visits by Adults for Dental Conditions in Maryland

Financial Impact of Emergency Department Visits by Adults for Dental Conditions in Maryland Financial Impact of Emergency Department by Adults for Dental Conditions in Maryland Background Access to dental care remains challenging for many children and adults. Lack of preventive care services

More information